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Introduction
Osteoporosis is the most common bone disease, character-ized by reduced bone mass and altered microarchitecture, 
therefore, associated with an increased fracture risk.1 Con-
sidering the aging trend in the population worldwide, the preva-
lence of osteoporosis is increasing rapidly. It is estimated that the 
fragility rate, which was about 1.7 million in 1999, would reach 
8.3 million in 2050.2 Therefore, osteoporosis and its complica-
tions impose a heavy burden on the society. Figure 1 shows the 
high risk of a major osteoporotic fracture in a 65-year-old indi-
vidual with a priority fragile fracture in different parts of the 
world.
6LQFHWKHIUDFWXUHLVPDLQO\WKH¿UVWV\PSWRPof osteoporosis, a 
large number of the patients, particularly in developing countries, 
remain undiagnosed and untreated, while osteoporosis is both pre-
ventable and treatable. 3 
In order to prevent the disease and its complications, the preva-
lence of the disease and its risk factors should be well known. 
This is while the majority of the studies conducted on this matter, 
in different parts of the world, suffer several shortcomings and 
discrepancies. Similarly, several studies have been conducted re-
cently in different parts of Iran; their results revealed that osteo-
porosis is becoming a health priority in the country.4 According 
to these results; the prevalence of osteoporosis and osteopenia is 
about 22% and 59.9% in women aged 50 years and over, respec-
tively. As for men of the same age group, the rate is about 11% and 
50.1%, correspondingly.5,6 
These data are mainly based on the results of different phases 
of the Iranian Multicenter Osteoporosis Study (IMOS) conducted 
by the Osteoporosis Research Center of the Endocrinology and 
0HWDEROLVP5HVHDUFK,QVWLWXWHDI¿OLDWHGZLWK7HKUDQ8QLYHUVLW\
of Medical Sciences in collaboration with the Iranian Ministry of 
Health and Medical Education. This study aimed to assess bone 
KHDOWK DQG WKH SUHYDOHQFH RI YLWDPLQ' GH¿FLHQF\ LQ GLIIHUHQW
parts of Iran. Each phase was conducted in different provinces 
with various altitudes, latitudes and lifestyle habits; therefore the 
¿QDOresults could be generalized to the country.
7KH¿UVWSKDVHRIWKHVWXG\ZDVFRQGXFWHGLQWKH¿YHPDLQFLWLHV
in Iran, including: Tehran, Shiraz, Bushehr, Mashhad, and Tabriz 
in 2000.7 The second phase was conducted in Sari and Yazd in 
2003.8 The third phase was conducted in Arak and Sanandaj in 
2012. 
This article presents the protocol used in the third phase of the 
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study. It was designed based on the experiences gathered in the 
previous phases, to overcome the experienced shortcomings, par-
ticularly subject loss. The questionnaire applied in this study was 
developed based on a thorough literature review of the risk factors 
and secondary causes of osteoporosis, and was then approved by 
an expert panel.9–11 
The majority of the existing studies aim to consider a certain 
aspect of osteoporosis however; this study provides the informa-
tion needed for policy makers and researchers to study different 
osteoporosis-related issues. The authors of this study believe the 
protocol can help policymakers in different parts of the world, 
particularly developing countries, gather accurate information on 
different aspects of bone health.
Material and Methods
The third phase of IMOS was conducted in Arak and Sanandaj. 
Arak, located at 34°5’8”N/49°41’2”E, 1,718 m (5,636 ft) is the 
capital of Markazi Province, Iran. In the latest census, the popula-
tion of this major Iranian industrial city was 526,182. Sanandaj, 
located at 35.2458° N, 47.0092° E, 1,538 m (5,046 ft), is the capi-
tal of the Kurdistan Province, Iran. According to the latest census 
performed in 2011, 311,446 people live in this city. The economy 
of Sanandaj is based upon the production of carpets, processed 
KLGHVDQGVNLQVPLOOHGULFHUH¿QHGVXJDUZRRGZRUNLQJ, cotton 
weaving, metalware and cutlery.
This study was conducted through a one–stage cluster sampling 
technique in winter 2011. The protocol of this study was approved 
by the Ethics Committee of the Endocrinology and Metabolism 
5HVHDUFK ,QVWLWXWH (05, DI¿OLDWHGZLWK Tehran University of 
Medical Sciences. Considering the results of the¿UVWSKDVHOXP
bar osteoporosis = 13%, accuracy 2.5%), 700 individuals were
needed in each city. The sample size was increased by 1.5 times 
after design-effect adjustments for the used cluster sampling tech-
nique. Thus, 1050 individuals were needed in each city. As a re-
sult, 70 clusters with 15 individuals in each cluster were recruited. 
The population-based study was conducted on all Iranian adults, 
aged 20 years and above, from the urban areas of Arak and Sanan-
daj. Non-Iranians and individuals, who had moved to these cities 
within the last 12 months, were not included in the study. Indi-
viduals with any mental/psychological problems, those unable to 
cooperate with the interviewers were excluded. Moreover, those 
with deformity in the spine, hip or lower extremities that would 
affect the BMD results, those who weighed more than 120 kg as 
well as those hospitalized for more than 2 weeks or immobilized 
for more than 3 consecutive months were dismissed. Individu-
als suffering from infertility, acute/chronic renal failure, advanced 
liver failure, any kind of cancer, chronic diarrhea (for more than 
2 weeks) and mal-absorption as well as those taking any type of 
vitamin D in the past 6 months, were also excluded. 
In this regard, a list of the households in each city was prepared 
based on the results of the latest census. A total of 70 households 
was randomly selected in each city. Each of these households was 
considered as a “cluster.” All the adults who met the inclusion 
criteria in these families and adjacent households, based on the 
census list, were recruited until 15 individuals were included in 
each cluster. 
The interviewers were asked to visit the households in the af-
Figure 1. Ten year probability of a major osteoporotic fracture for a 65-year-old person with a priority fragile fracture adopted from International Osteo-
porosis Foundation website.30
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ternoons, which was a better time for all family members. If each 
of the individuals were not present at home after three stopovers, 
another adult was included as said above. The individuals, who 
agreed to sign an informed consent form, wereDVNHGWR¿OODTXHV-
tionnaire at the time of the visit and then referred for laboratory 
and bone mineral density testing upon the arranged time. 
In order to assess the knowledge of women regarding osteopo-
rosis, a questionnaire was developed toEH¿OOHGE\ WKH IHPDOH
head of household or the oldest woman living in the house.12 In 
case the oldest woman living in the house was unable to answer 
the questions for any reason, after three visits, the questionnaire 
ZDV¿OOHGRXWE\WKHQH[WROGHVWIHPDOHIDPLO\PHPEHU. To the 
EHVWRIRXUNQRZOHGJHWKLVLVWKH¿UVW population-based study to 
measure the knowledge of the Iranian female family members on 
osteoporosis and its complications, risk and protective factors. It 
should be noted that to reduce theLQÀXHQFHRILPSOLFLWELDVWKLV
TXHVWLRQQDLUHZDVDOZD\V¿OOHGSULRU to the main questionnaire.
The main questionnaire comprised of several sections including: 
demographic information (age, gender, level of education, and 
marital and socioeconomic status), reproductive factors (only in 
women), lifestyle habits (sun exposure, exercising, smoking and 
alcohol abuse habits), family and personal medical history and 
drug use (with focus on diseases and medications affecting bone 
metabolism). Sensible sunlight exposure was assessed with an in-
dex, calculated from the number of hours spent each day in the 
sun, weighted according to the amount of body (less/more than 
5% (equal to hands and face) exposed to the light.13 In the repro-
ductive factors’ section, the breastfeeding duration was calculated 
by adding the breastfeeding time in each pregnancy. Menopause 
ZDVGH¿QHGDVWKH time when there has been no menstrual periods 
for 12 consecutive months and no other biological or physiologi-
cal cause canEHLGHQWL¿HG14*OXFRFRUWLFRLGXVHZDVGH¿QHGDV
the use of at least 7.5 mg of prednisolone or its equivalents for 
more than three months.15 The individuals were also asked about 
possible history of osteoporosis (previous BMD testing, the use of 
calcium and vitamin D supplements and anti-osteoporosis drugs 
and compliance with treatment) and fracture in themselves and 
¿UVWGHJUHHIDPLOLHV)UDJLOLW\IUDFWXUHLVGH¿QHGE\WKH:+2 as 
³DIUDFWXUHFDXVHGE\LQMXU\WKDWZRXOGEHLQVXI¿FLHQW to fracture 
a normal bone...the result of reduced compressive and/or torsional 
strength of bone”.16 Clinically,  fragility IUDFWXUHFDQEHGH¿QHG
as one, which   occurs as a result of a minimal trauma, such as 
a fall from a standing height or less. The interviewers were also 
asked about the 3-month dietary intake of calcium and vitamin D 
through a Food Frequency Questionnaire (FFQ). The question-
naire also assessed the individual’s habit of drinking tea, coffee 
and soft drinks.17 It should be added that the questionnaires were 
designed in a way that would facilitate the interview process and 
reduce the data entry error.
The individuals were sent to a certain laboratory, where 20 cc 
of fasting venous blood samples were taken. About 15cc of the 
blood was kept in plain tubes and 5cc in Ethylenediaminetetraace-
tic acid (EDTA) tubes. Samples (plain tube) were centrifuged at 
3000 RPM for 10 minutes and serum was extracted. Serum and 
whole blood samples were kept at -70 °C and then sent to the 
reference laboratory in Tehran. 
Serum Albumin, Alkaline-phosphatase, Calcium and Phospho-
rus levels were analyzed by Bromocresol green, DGKC, Arsenazo 
and molybdate methods respectively using Pars Azmoon Kit; Iran. 
Creatinine levels were analyzed by the Jaffe method using Man 
Kit, Iran. Serum levels of PTH, and Bone alkaline phosphatase 
were measured by ELISA method using Immunodiagnostic sys-
tem kits. Competitive ELISA using Enzymoimmunoassay with 
CV of 8% was used for 25(OH)D. Immunodiagnostic systems 
were used in all the three tests and calibration and quality control 
were performed based on the manufacturers’ guideline and using 
the available kits in the package. The whole blood sample was 
collected in an EDTA tube and used for genetic studies. Genomic 
DNA was extracted using the phenol chloroform technique. After 
designing the appropriate primers, Restriction Fragments length 
polymorphism (RFLP) was applied for genotyping to assess the 
frequency of the Vitamin D Receptor Gene (VDR) variants at end 
3’ gene (EcoRV, Bsm I, Taq I ApaI) and the 5’ region (FokI) in 
general Iranian population. The genotyping results were validated 
and approved by Sequencing.
Quality control was carried out regularly. Unacceptable range 
results, based on Westgard rules, were re-investigated. High-con-
centration samples (according to reportable range claimed by the 
manufacturers) were diluted to a concentration suited to measure-
ment based on the kit instructions.
The individuals were then sent to a BMD clinic, where they 
underwent an L2–L4 antero-posterior lumbar spine, hip and its 
sub-regions DXA study by a trained operator according to the 
manufacturer’s instruction. A Hologic Discovery-Wi (Hologic 
Inc, Waltham, Massachusetts, USA) and a Norland XR46 (Nor-
land Corp., Fort Atkinson, WI) were used in Arak and Sanandaj, 
respectively. Results were expressed as T- and Z-scores. Quality 
control procedures were carried out in accordance with the manu-
facturer’s recommendations. In each city, the instrument variation 
was determined regularly by a weekly calibration procedure using 
a phantom supplied by the manufacturer (the phantom equilib-
rium was sent from one city to another after each testing). The 
interdevice variance was checked several times during the study 
period. There was an irrelevant small difference between the re-
ported measures, which was negligible. Precision error in BMD 
measurements was 1% – 1.5% in the lumbar and 2% – 3% in the 
femoral regions. Standardized BMD (sBMD), which would not 
differ by more than 3% – 5 % of the different machines, were used 
to compare the results between the cities.18,19
Based on the World Health Organization Study Group recom-
PHQGDWLRQ %0' YDOXHVZHUH FODVVL¿HG DV QRUPDOosteopenic 
and osteoporotic.20 
In the clinic, the anthropometric measurements were also per-
formed. The measurements, including weight, height, waist and 
hip circumferences were obtained with light clothing and without 
shoes by trained technicians using similar instruments and fol-
lowing international guidelines.21 Quality control for all measure-
ments was monitored regularly.
The height (to the nearest 0.1 cm) and the weight (to the nearest 
0.1 kg) were measured using a wall-mounted stadiometer (Seca) 
and a mobile digital scale (Seca, Hamburg, Germany), respective-
ly. The BMI was calculated by dividing body weight by the height 
squared (kg/m2). The waist and hip circumference were measured 
XVLQJDQRQHODVWLFÀH[LEOHDQWKURSRPHWULFWDSHWRthe nearest 0.1 
cm) in the standing position. The tape was applied horizontally 
midway between the lowest rib margin and the iliac crest for WC 
and the widest point over the buttocks for HC measurements. The 
waist to hip ratio (WHR) was calculated by dividing WC by the 
HC.22 Individuals were then categorized according to their base-
line BMI values (XQGHUZHLJKWQRUPDOZHLJKW±
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overweight 25 – 29.9, and REHVHNJP
All the questionnaires were checked in two steps by the provin-
cial supervisor (in each province) and  the administrative supervi-
sor (in the EMRI in Tehran). The questionnaires with missing or 
unacceptable data were returned to the interviewers for recheck. 
7KH¿QDOL]HGTXHVWLRQQDLUHVDORQJZLWKWKH%0'DQGlaboratory 
results were entered in an Access Databank developed for this 
project. 
Statistical analysis
All statistical analyses were performed with SPSS 13.0 for Win-
dows (SPSS, Chicago, IL, USA). Means ± SD were used to ex-
press standard descriptive statistics. Categorical variables were 
expressed as percentages. The normality assumption was checked 
using Kolmogorov-Smirnov test. The skewed or not-normally 
distributed variables were transformed and then ANOVA or t-test 
was used to compare quantitative variables, whereas chi-square 
was used for the qualitative ones. 
Considering the population-based nature of the study, the weight 
of age and sex groups were implemented during data analysis 
based on the latest population census data carried out at national 
level in 2010.23 In this regard, age and sex-adjusted prevalence of 
YLWDPLQ'GH¿FLHQF\RU LQVXI¿FLHQF\ZHUHFDOFXODWHG ,QRUGHU
to study different factors affecting the risk of developing osteo-
porosis, the individuals were categorized into four main groups: 
premenopausal and postmenopausal women, men aged less than 
50 and men aged 50 years and over. WHOFODVVL¿FDWLRQQRUPDO
osteopenia and osteoporosis) was used to categorize BMD val-
ues in postmenopausal women and men aged 50 years and over.24 
This is while BMD values were divided into normal and low bone 
mass in the other two groups.
In accordance with the sampling method, survey Data Analysis 
was used to calculate points and interval estimation of the primary 
RXWFRPHSUHYDOHQFHRIYLWDPLQ'GH¿FLHQF\DQGLQVXI¿FLHQF\DV
well as the mean and standard deviation of serum levels of vita-
min D in the studied population), using STATA ver. 11.1. Logistic 
regression, using survey data analysis commands in STATA Pack-
age, was applied to assess the risk or protective factors for osteo-
SRURVLVDQGYLWDPLQ'GH¿FLHQF\3YDOXHVORZHUWKDQ were 
FRQVLGHUHGDVVWDWLVWLFDOO\VLJQL¿FDQW
Socioeconomic status (SES) is the combination of an individu-
al’s level of education and work experience as well as the individ-
ual’s and family’s economic and social position based on income, 
education, and occupation.25 When analyzing SES, the individual 
and household income as well as the education level and occu-
pation of each of the family members were assessed. Consider-
ing the fact that an accurate estimate on individual’s income is 
not always possible, personal and household asset assessments 
were used in the study. Thus, SES was measured based on four 
variables: level of education, residence place index (calculated 
by multiplying 10 percent of living area square footage to 5 for 
owned houses and 1 for rental, company and government houses), 
LQGLYLGXDO¿YHLWHPV with similar weights) and household assets 
(six items with similar weights). The assets mentioned in this sec-
tion are included in the list only if they belong to the individual or 
shared by the family members and are not applied for work pur-
poses. The resulted variable, calculated as a Z-score, was desig-
nated as the socioeconomic status and was used to divide patients 
into SES tertiles (low, medium, high). The use of a constant C (C 
= 2 in both provinces) greatly reduced the possibility of a negative 
Z-score in our study. A detailed explanation of the SES model can 
be found elsewhere.26
Based on 25(OH)D values, subjectsZHUHFODVVL¿HGDVWKRVHVXI-
IHULQJIURPYLWDPLQ'GH¿FLHQF\QJP/ LQVXI¿FLHQF\
PLOGGH¿FLHQF\WRQJP/DQGVXI¿FLHQF\KLJKHUWKDQ
30 ng/mL).27
Discussion
Before any decision targeting osteoporosis could be made at na-
tionalOHYHOSROLF\PDNHUVVKRXOGKDYHVXI¿FLHQWLQIRUPDWLRQRQ
the prevalence ofRVWHRSRURVLVDQGYLWDPLQ'GH¿FLHQF\LWVULVN
factors and compliance with treatment in the studied population. 
7KHUHIRUHWKH¿QDODLP of many national programs such as IMOS 
is to assess bone health in different geographical areas, ethnicities, 
races and lifestyles. These studies should be designed not only 
to gather accurate data but also to reduce data loss. Moreover, in 
view of the limited available resources, they should help provide 
policy makers and researchers with comparable and generalizable 
results. 
 To the best of our knowledge, while many studies have been 
conducted on various aspects of osteoporosis in different parts of 
the world, there are not many published protocols for the assess-
ment of risk factors and secondary causes of osteoporosis and vi-
tamin'GH¿FLHQF\H[LVW28
The present protocol was developed by an expert panel in ORC 
in collaboration with MoHME, the two main organizations to 
study bone health in Iran. 
This protocol was developed based on a literature review and 
the experience gained by the members of these two institutions in 
WKH¿UVWWZRSKDVHVRIWKHSRSXODWLRQEDVHG,0267KHVH studies 
were conducted in different Iranian provinces located in different 
altitudes and latitudes, where the habitants had different genetic 
backgrounds and living habits. As a result, phase 3 was designed 
to take into account such diversities. 
In this phase, we have tried to improve the protocol to over-
FRPH GH¿FLWV LQ the study design, variability in measurements 
particularly in measuring circulating levels of 25-hydroxyvitamin 
D [25(OH)D].29 In addition, blood samples were obtained in mid-
winter, when the individualsZHUHH[SRVHGWRLQVXI¿FLHQWVXQOLJKW
for at least four months and experienced little or no cutaneous 
synthesis of vitamin D. We also recommended the use of standard 
BMD, so that the BMD results could be compared regardless of 
the device. However, it should be noted that the personal medical 
history and drug use in this questionnaire is based on self-report 
and may not be accurate. 
In conclusion, several studies have assessed bone health in dif-
ferent populations, but many RI WKHPVXIIHU IURPYDULRXVGH¿-
ciencies and bias. The authors believe their questionnaire can be 
applied as a reference questionnaire in all similar studies, as its re-
liability and validity has been studied. Data gathered through this 
questionnaire could provide the policymakers with more accurate 
and comparable information on the nature and the prevalence of 
WKHGLVHDVH WKHUHIRUH DUHDVSHFL¿FPHDVXUHVwould be adopted 
to overcome the condition and its burden, which poses a heavy 
burden on the society.
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